|
Originally published In Press as doi:10.1074/jbc.M110444200 on February 19, 2002
J. Biol. Chem., Vol. 277, Issue 19, 16365-16370, May 10, 2002
Complementary Combining Site Contact Residue Mutations of the
Anti-digoxin Fab 26-10 Permit High Affinity Wild-type Binding*
Mary K.
Short §¶,
Rustem A.
Krykbaev ¶ ,
Philip D.
Jeffrey**, and
Michael N.
Margolies 
From the Antibody Engineering Laboratory,
Department of Surgery, Massachusetts General Hospital, Boston,
Massachusetts 02114 and the ** Department of Cellular
Biochemistry and Biophysics, Memorial Sloan-Kettering Cancer
Center, New York, New York 10021
Antibody 26-10, obtained in a secondary
immune response, binds digoxin with high affinity
(Ka = 1.3 × 1010
M 1) because of extensive shape
complementarity. We demonstrated previously that mutations of the
hapten contact residue HTrp-100 to Arg (where H refers to the
heavy chain) resulted in increased specificity for digoxin analogs
substituted at the cardenolide 16 position. However, mutagenesis of
H:CDR1 did not result in such a specificity change despite the
proximity of the H:CDR1 hapten contact residue Asn-35 to the
cardenolide 16 position. Here we constructed a bacteriophage-displayed
library containing randomized mutations at H chain residues 30-35 in a
26-10 mutant containing Arg-100 (26-10-RRALD). Phage were selected by
panning against digoxin, gitoxin (16-OH), and 16-acetylgitoxin coupled to bovine serum albumin. Clones that retained wild-type Asn at position
35 showed preferred binding to gitoxin, like the 26-10-RRALD parent.
In contrast, clones containing Val-35 selected mainly on
digoxin-bovine serum albumin demonstrated a shift back to wild-type specificity. Several clones containing Val-35 bound digoxin with increased affinity, approaching that of the wild type in a few instances, in contrast to the mutation Val-35 in the wild-type 26-10
background, which reduces affinity for digoxin 90-fold. It has
therefore proven possible to reorder the 26-10 binding site by
mutations including two major contact residues on opposite sides of the
site and yet to retain high affinity for binding for digoxin. Thus,
even among antibodies that have undergone affinity maturation in
vivo, different structural solutions to high affinity binding may be revealed.
*
This work was supported by Grant HL47415 from the National
Institutes of Health (to M.N.M.) and Grant CA24432 from the National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Hematology/Oncology, Children's Hospital
Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229.
¶
Both authors contributed equally to this work.
Present address: Dept. of Respiratory Diseases, Wyeth
Research, 200 Cambridge Park Dr., Cambridge, MA 02140.

To whom correspondence should be addressed: Dept. of Surgery,
Massachusetts General Hospital, 15 Parkman St., WACC 465, Boston, MA
02114. Tel.: 617-726-7798; Fax: 617-726-6802; E-mail:
mmargolies@partners.org.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Rajpal, N. Beyaz, L. Haber, G. Cappuccilli, H. Yee, R. R. Bhatt, T. Takeuchi, R. A. Lerner, and R. Crea
A general method for greatly improving the affinity of antibodies by using combinatorial libraries
PNAS,
June 14, 2005;
102(24):
8466 - 8471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Valjakka, A. Hemminki, S. Niemi, H. Soderlund, K. Takkinen, and J. Rouvinen
Crystal Structure of an in Vitro Affinity- and Specificity-matured Anti-testosterone Fab in Complex with Testosterone. IMPROVED AFFINITY RESULTS FROM SMALL STRUCTURAL CHANGES WITHIN THE VARIABLE DOMAINS
J. Biol. Chem.,
November 8, 2002;
277(46):
44021 - 44027.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|